Home › Funds › Vivo Capital, LLC › MNPR
Vivo Capital, LLC position in MNPR
Monopar Therapeutics Inc · Health Care
Vivo Capital, LLC reported holding 90,500 shares of MNPR (Monopar Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$7.2M, representing 0.82% of its reported portfolio and ranking #32 among its reported holdings. Vivo Capital, LLC has disclosed MNPR holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's MNPR position evolved
Vivo Capital, LLC first disclosed a stake in MNPR in Q3 2025 at 90,500 shares (US$7.4M). The position peaked in Q2 2026 at 90,500 shares, worth US$8.4M. Across 5 filings, Vivo Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 90,500 shares valued at US$7.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 90.50K | $7.39M | New |
| Q4 2025 | 90.50K | $5.91M | Hold |
| Q1 2026 | 90.50K | $4.96M | Hold |
| Q2 2026 | 90.50K | $8.38M | Hold |
| Q3 2026 | 90.50K | $7.21M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MNPR and 13F data
MNPR (Monopar Therapeutics Inc) is a Health Care company. 76 other funds we track also report a position in MNPR — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$61.8M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$30.0M), Saturn V Capital Management LP (US$28.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MNPR
- RA CAPITAL MANAGEMENT, L.P. 667.21K sh · $61.78M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 323.75K sh · $29.98M · Q2 2026
- Saturn V Capital Management LP 311.98K sh · $28.89M · Q2 2026
- Siren, L.L.C. 270.12K sh · $21.52M · Q3 2026
- ADAR1 Capital Management, LLC 217.59K sh · $20.15M · Q2 2026
- TCG Crossover Management, LLC 203.33K sh · $18.83M · Q2 2026
- Ikarian Capital, LLC 47.86K sh · $4.43M · Q2 2026
- STEMPOINT CAPITAL LP 30.12K sh · $2.79M · Q2 2026
- Ishara Investments LP 12.30K sh · $1.14M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held MNPR?
Vivo Capital, LLC has disclosed MNPR holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Vivo Capital, LLC's current position in MNPR?
As of Q3 2026, Vivo Capital, LLC holds 90.50K shares of MNPR (Monopar Therapeutics Inc), valued at $7.21M, representing 0.82% of its reported portfolio and ranking #32.
Has Vivo Capital, LLC been buying or selling MNPR?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in MNPR. The position peaked in Q2 2026 at 90.50K shares.
Which other funds hold MNPR?
Other major institutional holders of MNPR include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Saturn V Capital Management LP, among 76 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.